Regulatory ApprovalFormycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® 25.02.2025 / 06:30 CET/CESTThe issuer is solely ...

EQS-News: Formycon AG / Key word (s): Regulatory Approval Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® ...

J&J said it is seeking a preliminary injunction for Samsung Bioepis' close copy of Stelara over an unauthorized sublicense ...

Revenues in the biopharma industry continued to boom in the fourth quarter of last year, following a pattern seen ...

Coming in first on the list of Top 25 Pharma Companies US Rx is AbbVie, reaching $41,857m in US Rx revenue in 2023 and ...

Growth stocks can help to supercharge your investment portfolio and boost your retirement fund. The key, however, is to ...

More than a third (33%) of essential generic medicines were withdrawn from the Portuguese market in the last ten years, ...

The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

Swiss generics and biosimilars major Sandoz has announced the launch of Pyzchiva (ustekinumab-ttwe) in the USA. From today, ...

The global penicillin drug market size was valued at US$ 8.71 billion in 2023 and is projected to reach US$ 12.08 billion by 2032, registering a CAGR of 3.7% during the forecast period from 2024 to ...

Onychomycosis Treatment MarketThe global onychomycosis treatment market is projected to grow from USD 4,738.3 million in 2023 to USD 10,608.8 million by 2033, exhibiting a robust CAGR of 8.4% during ...

Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed MM patients Approval based on positive results from ...